Why Aren't There More New Antibiotics? The Pipeline Problem Behind Rising Resistance
Written and approved by Dr. Jasmine Bonder, DNP, APRN and Dr. Adam Bonder, MD
If antibiotic resistance is one of the biggest health challenges of the century, you'd expect new antibiotics to be rolling out constantly. There's growing demand. There's growing need. There are patients cycling through infection after infection, running out of options they can safely take.
And yet the pipeline is small. Really small.
The question most patients eventually ask is simple: why? If so many people need new antibiotics, why isn't the industry making them? The answer is uncomfortable, and it has very little to do with science.
Watch the Full Podcast Here
This article grew out of a conversation between Dr. Adam Bonder of Clinova Solutions, Hannah McKenney of Starling Medical, and Emily Melzer of LATDE Diagnostics about antibiotic stewardship, resistance, and why the pipeline for new antibiotics has fallen behind the need.

We recommend watching or listening to the full conversation for the complete discussion.
The Question Patients Rarely Get a Straight Answer To
When someone with recurrent UTIs runs out of antibiotic options, their first instinct is usually hope. There's got to be a new drug coming. Some researcher somewhere must be working on this. The system wouldn't just let people run out of options, right?
Not quite.
Yes, researchers are working on it. There are smart people with PhDs genuinely trying to solve this problem. But the speed at which real new antibiotics make it from research to a patient's pharmacy isn't anywhere close to what the current crisis actually needs.
The reason isn't a lack of ideas. It's a lack of money following the ideas.
The Unit Economics Problem
Pharmaceutical companies are businesses. Not in a dismissive way, just a factual one. They have to make money to exist, which means they have to invest in the drugs that produce a return.
Antibiotics, from a business perspective, are one of the worst possible investments in the industry. Here's why:
They cure the problem. A great antibiotic takes a sick person and makes them not sick, often within a week. That person then doesn't need the drug again.
They're used sparingly. Doctors are told to use antibiotics only when truly needed, which means low prescription volume relative to many other drugs.
Resistance erodes the market. Even when a new antibiotic works today, resistance eventually catches up with it, often within years.
Development is expensive. Bringing a new antibiotic to market can cost hundreds of millions of dollars across research, clinical trials, and regulatory approval.
Patent protection is finite. By the time a drug reaches patients, much of its exclusive patent window has already been used up on development.
Compare that to a drug for a chronic condition like high cholesterol or diabetes, where a patient takes the medication every day for the rest of their life. The economics are completely different.
So from a pure business standpoint, a company has to ask: why would we spend hundreds of millions developing a drug that cures something quickly, is used rarely, loses effectiveness over time, and doesn't require ongoing use?
The honest answer, from a unit-economics perspective, is that they wouldn't. And many of them haven't.
What That Looks Like in Reality
Over the past few decades, most major pharmaceutical companies have scaled down or exited antibiotic research entirely. The companies still working on new antibiotics are often smaller, under-resourced, and running at risk of folding before they get a product across the finish line.
A number of promising antibiotic startups have gone bankrupt in recent years despite having drugs that worked, because they couldn't generate enough revenue to stay in business once their product launched. That's not a pipeline problem. That's a market failure.
Meanwhile, resistance keeps growing. Faster than new drugs can be developed. Faster than policy has adapted. Faster than most patients realize.
What This Means for Recurrent UTI Patients
If you've been cycling through antibiotics for recurrent UTIs, this reality has direct implications for your care.
The next antibiotic may not be coming. When your current options run out, there isn't necessarily a new drug waiting in the wings. The ones that do emerge are often reserved for the most resistant infections and may not be available in standard outpatient care.
Every antibiotic course matters more. Every unnecessary use adds to resistance pressure in your personal microbiome and in the community around you. There's no new drug ready to replace what's being eroded.
Prevention becomes more valuable, not less. The fewer antibiotics you need over your lifetime, the longer the ones that work for you will continue to work.
Right diagnosis matters more. Taking an antibiotic for something that isn't actually a UTI is a double hit: it doesn't treat your real problem, and it adds resistance pressure to the microbiome you'll need to rely on later.
Right duration and dose matter more. Longer antibiotic courses aren't always better. Research consistently shows that longer durations drive more resistance without improving outcomes.
The pipeline problem turns antibiotic stewardship from a nice idea into a necessity.
What Can Actually Help Right Now
The answer to the pipeline problem isn't just waiting for new drugs. It's using what we have more thoughtfully.
That means:
Catching developing infections earlier, before they require antibiotic treatment
Testing more accurately, so when antibiotics are needed, the right one gets prescribed the first time
Treating root causes, not just repeating episodes
Using non-antibiotic prevention strategies when clinically appropriate, including vaginal estrogen, methenamine hippurate, D-mannose, cranberry PACs, and bladder instillation therapy
Addressing microbiome factors, pelvic floor factors, and hormonal factors that may be driving recurrence
Working with clinicians who understand recurrent UTIs specifically, rather than cycling through generic urgent care visits
None of this requires a new antibiotic. All of it extends how long your current options continue to work for you.
How Clinova Fits In
Clinova Solutions is a clinician-led telehealth practice specializing in recurrent UTIs, chronic urinary conditions, and the broader intimate health concerns that often come with them. The model was built around a simple reality: patients can't afford to keep using antibiotics the way the system has been using them, because the system isn't building replacements fast enough.
Our approach is built around:
Clinician-led evaluation that considers your full history, not just today's symptoms
Non-antibiotic prevention strategies when clinically appropriate
Thoughtful antibiotic stewardship when antibiotics are needed
Continuity of care so your pattern gets understood, not just treated
Coordination with emerging tools and partners across urinary health
To take a more informed next step, you can:
Learn more or schedule a telehealth visit at Clinova.Solutions

Behind This Conversation
This article grew out of an ongoing conversation between Clinova Solutions, Starling Medical, and LATDE Diagnostics about where UTI care, prevention, rapid diagnostics, and antibiotic stewardship are heading.
Dr. Adam Bonder, MD, MBA — Medical Director, Clinova Solutions
Adam shapes the clinical thinking behind Clinova's approach to recurrent and chronic urinary conditions and Clinova's work with partners across urinary health. 🔗 Connect on LinkedIn: https://www.linkedin.com/in/adam-j-bonder-md-mba-83b7a254/
Hannah McKenney, MS — Co-Founder, Starling Medical
Hannah leads Starling Medical and is helping drive the conversation around at-home, longitudinal urinary health monitoring and what more connected, preventative urinary care could look like for patients. 🔗 Connect on LinkedIn: https://www.linkedin.com/in/hmck96/
Emily Melzer, PhD — Founder, LATDE Diagnostics
Emily is a microbiologist with a bachelor's and PhD in microbiology, including research into bacterial cell surface biology and antimicrobial resistance. Her work at LATDE Diagnostics focuses on bringing rapid, instrument-free antibiotic susceptibility testing to any care setting, with a particular emphasis on health equity and reaching patients in rural, lower resource, and underserved settings. 🔗 Connect on LinkedIn: https://www.linkedin.com/in/emily-melzer/
This article is for educational purposes only and is not a substitute for individualized medical advice. Please consult a qualified clinician about your specific symptoms and health history.

Comments